Adrian Newman-Tancredi

NeuroAct Communication is a consulting service founded by Adrian Newman-Tancredi.



Adrian's strategy for successful drug discovery in neuropsychiatry and neurology is based on close integration of molecular, neurochemical and behavioural pharmacology.
  • Multi-disciplinary characterisation of NCEs.

  • Optimized in vitro screening criteria.

  • Early stage inclusion of whole-animal assays.

  • Thorough candidate profiling before development decisions.

For more information Contact


Executive Profile


Adrian Newman-Tancredi Ph.D., D.Sc. has broad expertise in neuropharmacology and pre-clinical drug discovery. See Areas of expertise.

As a neuropharmacologist with two decades of proven achievement in industrial "drug hunting", Adrian personally participated in the identification and characterization of novel antipsychotics, antidepressants and analgesics at the Servier Research Institute (Paris, France; 1993-2002) and at Pierre Fabre Laboratories (Castres, France; 2002-2010). In 2010, he created an independent neuropharmacology consulting service (NeuroAct Communication) and then co-founded Neurolixis in 2011, a neuroscience-focused bioscience company, where he serves as Chief Scientific Officer. Adrian is Principal Investigator of several grants from the Michael J. Fox Foundation for Parkinson's research and from the International Rett Syndrome Foundation. Adrian was awarded a B.Sc. in Biochemistry (1988), a Ph.D. in Neuropharmacology (1992) and a D.Sc. (Higher Doctorate, 2013) at the University of Kent at Canterbury (U.K.).

Adrian acquired detailed program management experience of multidisciplinary neuropharmacology research with particular emphasis on integrating molecular, neurochemical and behavioral pharmacology. Adrian also possesses extensive experience leading project teams including medicinal chemists, early ADMET and preclinical development partners. He built international collaborations with academic researchers and managed preparation of drug development and Due Diligence dossiers. He is currently managing the preclinical characterization and development of drugs targeted at Parkinson's disease and at Rett syndrome, an orphan disorder.

Adrian has published over 140 research reports in peer-reviewed journals (see Publications) and given symposia presentations to a wide variety of audiences (academic and industrial researchers, clinicians, students, etc.). Adrian has also co-authored patents describing novel chemical entities (NCEs) and serves on the Editorial Boards of the International Journal of Neuropsychopharmacology and of Frontiers in Neuropharmacology. He is an active member of neuroscience-based professional associations and European Councillor of the International Society for Serotonin Research. Adrian is bi-national (anglo-italian) and tri-lingual (English, French, Italian).

For recommendations of Adrian's management skills and scientific competence see Endorsements.